Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2025-12-10 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT ON RESULTS OF THE ISSUANCE OF THE 2025 FOURTH TRANCHE OF SCI-TECH INNOVATION BONDS
Capital/Financing Update Classification · 1% confidence The document is an official announcement from Yankuang Energy Group regarding the successful issuance of a specific tranche of 'sci-tech innovation bonds'. It details the financial terms, issuance amount, interest rate, and underwriters of the debt instrument. This falls under the category of company fundraising and financing activities, which corresponds to the 'CAP' (Capital/Financing Update) filing type.
2025-12-10 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE INCLUSION OF GAVRETO (PRALSETINIB) IN THE 2025 NATIONAL REIMBURSEMENT DRUG LIST
Regulatory Filings Classification · 1% confidence The document is a 'Voluntary Announcement' issued by CStone Pharmaceuticals regarding the inclusion of their drug GAVRETO in the 2025 National Reimbursement Drug List. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it provides substantive business news rather than just announcing the availability of a report. As it is a general corporate announcement regarding business development, it falls under the 'Regulatory Filings' (RNS) fallback category.
2025-12-08 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies to report monthly movements in securities, including share capital, share options, and treasury shares. As it is a recurring regulatory filing detailing changes in securities and capital structure, it falls under the 'Regulatory Filings' category.
2025-12-04 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-12-02 English
Monthly Return
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. Since it is a recurring regulatory filing regarding share capital structure and does not represent a specific corporate action like a new share issue or a buyback (it reports 'Not applicable' for movements), it falls under the general regulatory filing category.
2025-12-02 English
CONNECTED TRANSACTION ACQUISITION OF 100% EQUITY INTEREST IN HIGH-END SUPPORT
M&A Activity Classification · 1% confidence The document is an official announcement by Yankuang Energy Group Company Limited regarding a 'Connected Transaction' involving the acquisition of 100% equity interest in High-End Support. It details the parties involved, the consideration, the valuation report, and the implications under the Hong Kong Stock Exchange Listing Rules. This fits the definition of a corporate announcement regarding M&A activity (specifically an internal group restructuring/acquisition).
2025-11-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.